Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 6/20 | 0.57 |
| ▸ | TACR1 | P25103 | 12/20 | 0.54 |
| ▸ | CCR2 | P41597 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975422 | 0.93 | CCR3 (0.55) | CCR3TACR1CCR2 | |
| SCHEMBL7938489 | 0.91 | CCR3 (0.59) | CCR3TACR1SIGMAR1 | |
| SCHEMBL16226687 | 0.89 | TACR1 (0.52) | CCR3TACR1 | |
| SCHEMBL7987228 | 0.87 | CCR3 (0.67) | CCR3TACR1CCR2 | |
| SCHEMBL6479126 | 0.85 | TACR1 (0.54) | CCR3TACR1CCR2SIGMAR1 | |
| SCHEMBL7926034 | 0.84 | TACR1 (0.48) | CCR3TACR1 | |
| SCHEMBL7934653 | 0.84 | CCR3 (0.60) | CCR3TACR1 | |
| SCHEMBL7925814 | 0.83 | CCR3 (0.50) | CCR3TACR1SIGMAR1 | |
| SCHEMBL7934776 | 0.82 | TACR1 (0.57) | CCR3TACR1CCR2 | |
| SCHEMBL7975478 | 0.82 | CCR3 (0.61) | CCR3TACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6191135-B1 | Neurokinin antagonists | BOEHRINGER INGELHEIM KG (DE) | 2001-02-20 | — | — | US | claimed |
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-6235732-B1 | RESPIRATORY SYSTEM DISORDERS; ANTIINFLAMMATORY AGENTS; SKIN DISORDERS | BOEHRINGER INGELHEIM KG (DE) | 2001-05-22 | — | — | US | disclosed |
| US-6191135-B1 | Neurokinin antagonists | BOEHRINGER INGELHEIM KG (DE) | 2001-02-20 | — | — | US | disclosed |
| US-5985881-A | TREATMENT AND PREVENTION OF RESPIRATORY DISORDERS, INFLAMMATORY EYE DISEASES, INFLAMMATORY SKIN DISEASES, INTESTINAL DISORDERS, OTHER INFLAMMATORY DISEASES | BOEHRINGER INGELHEIM KG (DE) | 1999-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | CCR3 282/4885TACR1 460/4885CCR2 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.